Form 4: Lilly Endowment Sells $168M+ Eli Lilly Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 205,782 shares of common stock on October 1, 2025, as part of a larger series of transactions.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), reported the sale of 205,782 shares of common stock.
• These transactions occurred on October 1, 2025, at weighted average prices ranging from $807.85 to $833.155 per share.
• The total value of shares sold in this filing amounts to approximately $168.89 million.
• Following these transactions, Lilly Endowment Inc. directly holds 95,141,978 shares of Eli Lilly & Co. common stock.
• This Form 4 represents transactions #31 through #55 of a total of 55 transactions, with another Form 4 filed on the same date covering the remaining transactions.
• The sales were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading schedule.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of insider transactions, specifically sales by a 10% owner. The transactions were made pursuant to a Rule 10b5-1 plan, which suggests a pre-scheduled divestment rather than an immediate reaction to new information, thus indicating a neutral sentiment regarding the company's prospects based solely on this filing.

Future Outlook

N/A. This filing reports past transactions and does not provide forward-looking statements or guidance.

Industry Context

N/A. This Form 4 filing details an insider stock transaction and does not provide information related to broader industry trends or competitors.

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of common stock. These transactions are disclosed as required for significant shareholders.

Stakeholder Impact

• Potential minor impact on shareholder sentiment due to a large institutional owner selling a significant number of shares.
• The transactions were executed under a Rule 10b5-1 plan, which may mitigate concerns about immediate negative signals from the sale.

Key Dates

Keywords

Eli Lilly, LLY, Lilly Endowment, Form 4, Insider Sale, Stock Transaction, 10b5-1 Plan, Pharmaceutical, Biotech